COLUMBUS (CMEK162B2301) - A Phase III randomized, 3-arm, open label, multicenter study of LGX818 plus MEK162 and LGX818 monotherapy compared with vemurafenib in patients with unresectable or metastatic BRAF V600 mutant melanoma
Laufzeit: 01.01.2014 - 31.12.2020
imported
Kurzfassung
A Phase III randomized, 3-arm, open label, multicenter study of LGX818 plus MEK162 and LGX818 monotherapy compared with vemurafenib in patients with unresectable or metastatic BRAF V600 mutant melanoma
Projekt der Hautklinik. Augenklinik nimmt als Kooperationspartner teil.
